Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk.
The mechanism(s) through which smoking influences the progression of atherosclerosis is poorly understood. Recent evidence suggests that oxidants present in the gas phase of cigarette smoke are involved. We exposed human plasma to the filtered gas phase of cigarette smoke to assess its effects on plasma components involved in the antiatherogenic reverse cholesterol transport pathway. In our model, freshly isolated plasma (24 mL) was exposed to filtered air or gas-phase cigarette smoke for up to 6 hours at 37 degrees C. Lecithin-cholesterol acyltransferase (LCAT) activity was dramatically inhibited by cigarette smoke. A single 15-minute exposure to the smoke from an eighth of a cigarette was sufficient to reduce LCAT activity by 7%; additional exposures resulted in further decreases in activity. At 6 hours, only 22% of control LCAT activity remained in plasma exposed to smoke. Compared with control, gas-phase cigarette smoke-exposed plasma possessed high-density lipoprotein (HDL) with increased (16%) negative charge and with cross-linked apolipoproteins AI and AII. These data demonstrate that gas-phase cigarette smoke can inhibit a key enzyme (LCAT) and modify an integral lipid transport particle (HDL) that are essential components for the normal function of the reverse cholesterol transport pathway. Gas-phase cigarette smoke-induced modification of the reverse cholesterol transport pathway may provide a new mechanistic link between cigarette smoke and coronary heart disease risk.
McCall
M R
MR
Department of Molecular and Nuclear Medicine, Lawrence Berkeley Laboratory, University of California, Berkeley 94720.
van den Berg
J J
JJ
Kuypers
F A
FA
Tribble
D L
DL
Krauss
R M
RM
Knoff
L J
LJ
Forte
T M
TM
D000328:Adult; D001053:Apolipoproteins / Q000737:chemistry; D001205:Ascorbic Acid / Q000097:blood; D003327:Coronary Disease / Q000209:etiology*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005978:Glutathione / Q000494:pharmacology; D006801:Humans; D008074:Lipoproteins / Q000737:chemistry; D008075:Lipoproteins, HDL / Q000737:chemistry*; D008297:Male; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000037:antagonists & inhibitors*; D010947:Plants, Toxic; D012307:Risk Factors; D012906:Smoke; D014026:Nicotiana; D014527:Uric Acid / Q000097:blood; D014810:Vitamin E / Q000097:blood
D001053:Apolipoproteins; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D012906:Smoke; D014810:Vitamin E; D014527:Uric Acid; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D005978:Glutathione; D001205:Ascorbic Acid